R. Medzhitov, C. Janeway, and . Jr, Innate immunity, Current Opinion in Immunology, vol.15, issue.1, pp.338-382, 2000.
DOI : 10.1016/S0952-7915(02)00019-5
URL : https://hal.archives-ouvertes.fr/hal-01438527

M. Lederman, A. Nicholson, and M. Cho, Biology of CCR5 and Its Role in HIV Infection and Treatment, JAMA, vol.296, issue.7, pp.815-841, 2006.
DOI : 10.1001/jama.296.7.815

H. Deng, R. Liu, and W. Ellmeier, Identification of a major co-receptor for primary isolates of HIV-1, Nature, vol.381, issue.6584, pp.661-667, 1996.
DOI : 10.1038/381661a0

T. Dragic, V. Litwin, and G. Allaway, HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5, Nature, vol.381, issue.6584, pp.667-73, 1996.
DOI : 10.1038/381667a0

R. Macarthur and R. Novak, Reviews Of Anti???infective Agents: Maraviroc: The First of a New Class of Antiretroviral Agents, Clinical Infectious Diseases, vol.47, issue.2, pp.236-277, 2008.
DOI : 10.1086/589289

V. Soriano, A. Geretti, and C. Perno, Optimal use of maraviroc in clinical practice, AIDS, vol.22, issue.17, pp.2231-2271, 2008.
DOI : 10.1097/QAD.0b013e3283136d95

S. Lieberman-blum, H. Fung, and J. Bandres, Maraviroc: A CCR5-receptor antagonist for the treatment of HIV-1 infection, Clinical Therapeutics, vol.30, issue.7, pp.1228-50, 2008.
DOI : 10.1016/S0149-2918(08)80048-3

J. Emmelkamp and J. Rockstroh, CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions ? review of the literature, Eur J Med Res, vol.12, pp.409-426, 2007.

V. Soriano, C. Perno, and R. Kaiser, When and how to use maraviroc in HIV-infected patients, AIDS, vol.23, issue.18, pp.2377-885, 2009.
DOI : 10.1097/QAD.0b013e328332d32d

P. Corbeau and J. Reynes, CCR5 antagonism in HIV infection: ways, effects, and side effects, AIDS, vol.23, issue.15, pp.1931-1974, 2009.
DOI : 10.1097/QAD.0b013e32832e71cd
URL : https://hal.archives-ouvertes.fr/hal-00429305

G. Alkhatib, The biology of CCR5 and CXCR4, Current Opinion in HIV and AIDS, vol.4, issue.2, pp.96-103, 2009.
DOI : 10.1097/COH.0b013e328324bbec

R. Rossi, M. Lichtner, and I. Sauzullo, Downregulation of Leukocyte Migration After Treatment With CCR5 Antagonist Maraviroc, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.54, issue.5, pp.13-14, 2010.
DOI : 10.1097/QAI.0b013e3181ed18f6

S. Ahuja, J. Gao, and P. Murphy, Chemokine receptors and molecular mimicry, Immunology Today, vol.15, issue.6, pp.281-288, 1994.
DOI : 10.1016/0167-5699(94)90008-6

D. Yang, Q. Chen, and Y. Le, Differential Regulation of Formyl Peptide Receptor-Like 1 Expression During the Differentiation of Monocytes to Dendritic Cells and Macrophages, The Journal of Immunology, vol.166, issue.6, pp.4092-4100, 2001.
DOI : 10.4049/jimmunol.166.6.4092

W. Shen, B. Li, and M. Wetzel, Down-regulation of the chemokine receptor CCR5 by activation of chemotactic formyl peptide receptor in human monocytes, Blood, vol.96, pp.2887-94, 2000.

Y. Le, M. Wetzel, and W. Shen, Desensitization of Chemokine Receptor CCR5 in Dendritic Cells at the Early Stage of Differentiation by Activation of Formyl Peptide Receptors, Clinical Immunology, vol.99, issue.3, pp.365-72, 2001.
DOI : 10.1006/clim.2001.5021

N. Dhillon, R. Williams, S. Callen, C. Zien, O. Narayan et al., Roles of MCP-1 in development of HIV-dementia, Frontiers in Bioscience, vol.Volume, issue.13, pp.3913-3931, 2008.
DOI : 10.2741/2979

L. El-asmar, J. Springael, S. Ballet, E. Andrieu, G. Vassart et al., Evidence for Negative Binding Cooperativity within CCR5-CCR2b Heterodimers, Molecular Pharmacology, vol.67, issue.2, pp.460-469, 2005.
DOI : 10.1124/mol.104.003624

G. Jones, C. Watera, and S. Patterson, Comparative loss and maturation of peripheral blood dendritic cell subpopulations in African and non-African HIV-1-infected patients, AIDS, vol.15, issue.13, pp.1657-63, 2001.
DOI : 10.1097/00002030-200109070-00008

C. Coleman and L. Wu, HIV interactions with monocytes and dendritic cells: viral latency and reservoirs, Retrovirology, vol.6, issue.1, pp.143-54, 2009.
DOI : 10.1186/1742-4690-6-51

B. Marin, R. Thiébaut, and H. Bucher, Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy, AIDS, vol.23, issue.13, pp.1743-53, 2009.
DOI : 10.1097/QAD.0b013e32832e9b78
URL : https://hal.archives-ouvertes.fr/inserm-00388946

O. Soehnlein and C. Weber, Myeloid cells in atherosclerosis: initiators and decision shapers, Seminars in Immunopathology, vol.107, issue.1, pp.35-47, 2009.
DOI : 10.1007/s00281-009-0141-z

M. Lichtner, M. Cuomo, and R. Rossi, Increased carotid intima media thickness is associated with depletion of circulating myeloid dendritic cells in HIV-infected patients on suppressive antiretroviral treatment, Atherosclerosis, vol.204, issue.2, pp.1-3, 2009.
DOI : 10.1016/j.atherosclerosis.2008.12.025

J. Pacanowski, S. Kahi, and M. Baillet, Reduced blood CD123+ (lymphoid) and CD11c+ (myeloid) dendritic cell numbers in primary HIV-1 infection, Blood, vol.98, issue.10, pp.3016-3037, 2001.
DOI : 10.1182/blood.V98.10.3016

M. Lichtner, R. Rossi, and M. Rizza, Plasmacytoid dendritic cells count in antiretroviral-treated patients is predictive of HIV load control independent of CD4+ T-cell count, Curr HIV Res, vol.6, pp.19-27, 2008.

A. Hardy, D. Graham, and G. Shearer, HIV turns plasmacytoid dendritic cells (pDC) into TRAIL-expressing killer pDC and down-regulates HIV coreceptors by Toll-like receptor 7-induced IFN-??, Proceedings of the National Academy of Sciences, vol.104, issue.44, pp.17453-17461, 2007.
DOI : 10.1073/pnas.0707244104
URL : https://hal.archives-ouvertes.fr/hal-00177945

M. Lichtner, C. Marañón, and P. Vidalain, HIV Type 1-Infected Dendritic Cells Induce Apoptotic Death in Infected and Uninfected Primary CD4 T Lymphocytes, AIDS Research and Human Retroviruses, vol.20, issue.2, pp.175-82, 2004.
DOI : 10.1089/088922204773004897

X. Gong, H. Feng, and S. Zhang, Increased expression of CCR5 in experimental autoimmune myocarditis and reduced severity induced by anti-CCR5 monoclonal antibody, Journal of Molecular and Cellular Cardiology, vol.42, issue.4, pp.781-91, 2007.
DOI : 10.1016/j.yjmcc.2007.02.003

J. Lim, C. Louie, and C. Glaser, Genetic Deficiency of Chemokine Receptor CCR5 Is a Strong Risk Factor for Symptomatic West Nile Virus Infection: A Meta???Analysis of 4 Cohorts in the US Epidemic, The Journal of Infectious Diseases, vol.197, issue.2, pp.262-267, 2008.
DOI : 10.1086/524691

A. Telenti, Safety concerns about CCR5 as an antiviral target, Current Opinion in HIV and AIDS, vol.4, issue.2, pp.131-136, 2009.
DOI : 10.1097/COH.0b013e3283223d76